MedPath

Acella Pharmaceuticals, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

45

FDA:45

Drug Approvals

Sodium Sulfacetamide

Approval Date
Sep 9, 2025
FDA

Gabapentin

Approval Date
Jul 30, 2025
FDA

Ciclopirox

Approval Date
Jan 18, 2024
FDA

PNV-Select

Approval Date
Jan 16, 2024
FDA

Prenaissance Plus

Approval Date
Jan 16, 2024
FDA

Prenaissance

Approval Date
Jan 16, 2024
FDA

Ciclopirox

Approval Date
Jan 16, 2024
FDA

Sodium Sulfacetamide 10 Sulfur 2 cream

Approval Date
Jan 15, 2024
FDA

PNV-DHA

Approval Date
Jan 15, 2024
FDA

PNV-DHA

Approval Date
Jan 15, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)
No trials found

News

FDA Approves Phase 2 Trial Modification for Abion's Novel Lung Cancer Combination Therapy

The FDA has approved modifications to the Phase 2 clinical trial for vabametkib, Abion's c-MET targeted anticancer drug, in combination with lazertinib for non-small cell lung cancer patients. The trial will evaluate this novel combination therapy in patients who have developed resistance to EGFR-targeted treatments, addressing a significant unmet need in NSCLC treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.